Previous 10 | Next 10 |
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.7% on the day to $25.75. IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted the...
2024-01-19 17:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.7% on the day to $25.75. IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted the...
2024-01-16 07:00:00 ET Summary Small cap stocks surged in the final two months of the year as the 10-year yield reversed direction. The Fed's actions in 2024 will determine the prospects for small cap stocks, with a rate cut in March improving their prospects. Small caps may f...
IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance PR Newswire SOUTH SAN FRANCISCO, Calif. , Jan. 7, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncolo...
2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...
2023-12-14 00:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-05 15:01:27 ET Summary Ideaya Biosciences uses synthetic lethality to target cancer cells and has seen its stock double since March. Synthetic lethality can selectively target cancer cells while sparing normal cells, offering a promising therapeutic strategy. Ideaya's ...
IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , Dec. 5, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discov...
2023-12-04 09:50:28 ET More on SPDR S&P 500 ETF Trust: Bears Refuse To Acknowledge New All-Time Highs In 2024 SPY Is A Buy According To The 200-Day Simple Moving Average When Do You Take Profits? Top 10 trades for 2024 - BofA S&P 500 hits new ...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer PR Newswire First-Patient-In (FPI) for Phase 1 combination treatment with IDE397, IDEAYA's MAT2A inhibitor, and Trodelvy ...
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors PR Newswire Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung an...
IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study PR Newswire 75% eye preservation rate (9 of 12 enucleation patients) ~67% (8 of 12 enucleation patients...